Critical Contrast: Aemetis (AMTX) vs. Its Peers

Aemetis (NASDAQ: AMTX) is one of 25 public companies in the “Industrial organic chemicals” industry, but how does it weigh in compared to its rivals? We will compare Aemetis to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

Insider and Institutional Ownership

How to Become a New Pot Stock Millionaire

15.9% of Aemetis shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Industrial organic chemicals” companies are owned by institutional investors. 24.1% of Aemetis shares are owned by insiders. Comparatively, 14.0% of shares of all “Industrial organic chemicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Aemetis and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aemetis $150.15 million -$30.30 million -1.53
Aemetis Competitors $3.36 billion $346.13 million 4.16

Aemetis’ rivals have higher revenue and earnings than Aemetis. Aemetis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Aemetis has a beta of -0.74, meaning that its stock price is 174% less volatile than the S&P 500. Comparatively, Aemetis’ rivals have a beta of 0.49, meaning that their average stock price is 51% less volatile than the S&P 500.

Profitability

This table compares Aemetis and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aemetis -20.19% N/A -36.85%
Aemetis Competitors -11.48% -11.19% -5.31%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Aemetis and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aemetis 0 2 1 0 2.33
Aemetis Competitors 119 474 736 25 2.49

Aemetis currently has a consensus price target of $2.00, suggesting a potential upside of 47.06%. As a group, “Industrial organic chemicals” companies have a potential upside of 15.32%. Given Aemetis’ higher probable upside, equities research analysts clearly believe Aemetis is more favorable than its rivals.

Summary

Aemetis rivals beat Aemetis on 10 of the 13 factors compared.

About Aemetis

Aemetis, Inc. operates as an international renewable fuels and bio-chemicals company in North America and India. It focuses on the production of advanced fuels and chemicals through the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into advanced bio refineries. The company owns and operates a biodiesel plant in Kakinada, India; and an ethanol plant in Keyes, California. Aemetis, Inc. sells biodiesel and glycerin to resellers, distributors, and refiners through its sales force and independent sales agents, as well as to brokers who resell the product to end-users. It also produces ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Q1 2018 Earnings Estimate for Shire Issued By SunTrust Banks
Q1 2018 Earnings Estimate for Shire Issued By SunTrust Banks
TMAC Resources  Forecasted to Post Q1 2018 Earnings of $0.05 Per Share
TMAC Resources Forecasted to Post Q1 2018 Earnings of $0.05 Per Share
Financial Analysis: Wolters Kluwer  & Thomson Reuters
Financial Analysis: Wolters Kluwer & Thomson Reuters
Head-To-Head Analysis: National CineMedia  vs. Naspers
Head-To-Head Analysis: National CineMedia vs. Naspers
The Children’s Place  & Its Peers Head-To-Head Analysis
The Children’s Place & Its Peers Head-To-Head Analysis
American Homes 4 Rent  Expected to Post Quarterly Sales of $251.71 Million
American Homes 4 Rent Expected to Post Quarterly Sales of $251.71 Million


Leave a Reply

© 2006-2018 Ticker Report. Google+.